SynAct Pharma AB Total Liabilities

Latest as of March 2026: Skr44.13 Million SEK ≈ $4.75 Million USD

SynAct Pharma AB total liabilities. Based on the latest financial reports, SynAct Pharma AB (SYNACT) has total liabilities worth Skr44.13 Million SEK (≈ $4.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of SynAct Pharma AB to evaluate the company's liquid asset resilience ratio.

Total Liabilities of SynAct Pharma AB (2014–2025)

Total liabilities of SynAct Pharma AB from 2014 to 2025. This chart illustrates how SynAct Pharma AB's total liabilities have evolved over time, based on quarterly financial data.

SynAct Pharma AB Competitors by Total Liabilities

The table below lists competitors of SynAct Pharma AB ranked by their total liabilities.

Company	Country	Total Liabilities
Parsan Makina Parcalari Sanayi AS IS:PARSN	Turkey	TL8.05 Billion
DAEYANG ELECTRIC.Co.Ltd KQ:108380	Korea	₩68.47 Billion
Zeotech Ltd AU:ZEO	Australia	AU$1.12 Million
Elentec Co. Ltd KQ:054210	Korea	₩430.25 Billion
Chyang Sheng Dyeing & Finishing Co Ltd TW:1463	Taiwan	NT$408.33 Million
Kandi Technologies Group Inc NASDAQ:KNDI	USA	$87.39 Million
ANDRADA MINING LTD. F:9IA	Germany	€43.56 Million
Nasmedia Co. Ltd KQ:089600	Korea	₩185.10 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down SynAct Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SynAct Pharma AB asset portfolio.

Liquidity & Leverage Metrics

SynAct Pharma AB Total Liabilities Ratios Explained

SynAct Pharma AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	5.74	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.23	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SynAct Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SynAct Pharma AB (2014–2025)

The table below shows the annual total liabilities of SynAct Pharma AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr50.23 Million ≈ $5.41 Million	-10.87%
2024-12-31	Skr56.35 Million ≈ $6.06 Million	+8.72%
2023-12-31	Skr51.83 Million ≈ $5.58 Million	+222.42%
2022-12-31	Skr16.08 Million ≈ $1.73 Million	-8.14%
2021-12-31	Skr17.50 Million ≈ $1.88 Million	+205.68%
2020-12-31	Skr5.72 Million ≈ $616.10K	-44.48%
2019-12-31	Skr10.31 Million ≈ $1.11 Million	+177.43%
2018-12-31	Skr3.72 Million ≈ $399.95K	+60.65%
2017-12-31	Skr2.31 Million ≈ $248.97K	-33.76%
2016-12-31	Skr3.49 Million ≈ $375.87K	+6027.54%
2015-12-31	Skr57.00K ≈ $6.13K	-29.63%
2014-12-31	Skr81.00K ≈ $8.72K	--

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$94.61 Million

Skr879.17 Million SEK

Market Cap Rank

#19205 Global

#335 in Sweden

Share Price

Skr15.70

Change (1 day)

-2.73%

52-Week Range

Skr10.66 - Skr24.20

All Time High

Skr143.40